PHASE Scientific secures $34m Series A for non-invasive diagnostics including world-first urine-based HPV test
A non-invasive approach to traditional procedures
PHASE Scientific, a Hong Kong-based biotechnology company, has raised $34 million in Series A financing to accelerate the development and commercialization of its urine-based diagnostic technology, with specific focus areas including women’s health, cancer detection, and infectious diseases.
The round is the largest Series A funding in Asia’s diagnostic technology sector since 2019.
The investment, led by a private equity fund managed by Value Partners Group, reflects growing investor interest in non-invasive diagnostic tools that can broaden access to early disease detection - particularly in underserved areas of women’s health. The funds will support PHASE Scientific’s R&D and commercialization of its proprietary PHASIFY™ platform, which significantly improves biomarker capture in urine-based samples by more than ten times compared to current standards.
PHASE Scientific says that it is the only player developing a pipeline of urine-based liquid biopsy diagnostics, offering a non-invasive alternative to traditional procedures.
World-first urine-based HPV test
For women’s health specifically, this includes the world’s first urine-based HPV test, which has demonstrated 93.4% sensitivity in detecting precancerous cervical lesions and over 97% concordance with gold-standard physician-collected tests for high-risk HPV types. The innovation earned the Thomas V. Sedlacek, MD, Prize for Best Clinical Research Abstract at the 2025 American Society for Colposcopy and Cervical Pathology (ASCCP) Annual Scientific Meeting and was featured at the Chinese Society for Colposcopy and Cervical Pathology (CSCCP) Conference, reflecting growing international interest and recognition.
“The successful close of this landmark Series A financing validates the transformative potential of our technology and the growing global demand for accessible, accurate early disease detection,” said Dr. Ricky Chiu, Founder, Chairman, and CEO of PHASE Scientific.
“With this capital, we will accelerate R&D and commercialization efforts to bring a comprehensive suite of next-generation urine-based diagnostics to market. Our mission is to empower millions worldwide with non-invasive, user-friendly testing that can save lives through earlier intervention.”
PHASE Scientific’s broader diagnostic portfolio includes over 30 commercialized products across oncology, respiratory, gastrointestinal, pediatric, sexual, and women’s health. The company has delivered over 100 million diagnostic tests globally and conducted more than 8 million laboratory tests.
Commenting on the investment, Dr. Chuen Yan Leung, Partner (Healthcare Investments) of Value Partners Group, said:
“We are delighted to become a partner of PHASE Scientific as it rapidly grows and addresses critical unmet needs in early disease detection. Its innovative technology represents a paradigm shift, offering an unparalleled combination of clinical precision and patient-centric solutions that accelerates the development of early disease detection.”
PHASE Scientific was founded in 2015 and operates across Hong Kong SAR, Southern California, and the Greater Bay Area in China. Its geographic footprint supports a cross-border model for innovation, development, and commercialization.
As non-invasive diagnostics become a larger part of healthcare infrastructure globally, PHASE Scientific’s work in women’s health exemplifies how emerging technologies can drive meaningful improvements in early detection and preventive care.